VEGFA and Insulin resistance: Similarly, Wu et al. found that administration of the VEGFA-neutralizing monoclonal antibody B.20-4.1, led to amelioration of high-fat diet-induced insulin resistance, principally due to improved insulin sensitivity in the liver and associated with decreased inflammatory markers [152] These results indicate that systemic inhibition of VEGFA affects multiple organs and tissues leading to improved glucose homeostasis, dominating over the local effect on adipose tissue, which would be expected to impair systemic metabolism.